These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1877538)

  • 1. Rapid removal of heparin from plasma by affinity filtration.
    Wenz B; Burns ER
    Am J Clin Pathol; 1991 Sep; 96(3):385-90. PubMed ID: 1877538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of undiagnosed coagulopathies using routine rapid heparin neutralization.
    Burns ER; Lee V; Wenz B
    Clin Lab Sci; 1995; 8(2):113-6. PubMed ID: 10150468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-step chromogenic equivalent of activated partial thromboplastin time evaluated for clinical application.
    Ponjee GA; Vader HL; de Wild PJ; Janssen GW; van der Graaf F
    Clin Chem; 1991 Jul; 37(7):1235-44. PubMed ID: 1855296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction.
    Byun Y; Yun JH; Han IS; Fu Y; Shanberge JN; Yang VC
    ASAIO J; 1995; 41(3):M301-5. PubMed ID: 8573812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.
    Favaloro EJ; Kershaw G; Mohammed S; Lippi G
    Semin Thromb Hemost; 2019 Feb; 45(1):22-35. PubMed ID: 30630206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of an automated coagulation analyzer to perform heparin neutralization with polybrene in blood samples for routine coagulation testing: practical, rapid, and inexpensive.
    Tientadakul P; Kongkan C; Chinswangwatanakul W
    Arch Pathol Lab Med; 2013 Nov; 137(11):1641-7. PubMed ID: 24168503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage.
    Kitchen S; Jennings I; Woods TA; Preston FE
    J Clin Pathol; 1996 Jan; 49(1):10-4. PubMed ID: 8666677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of heparin and protamine from plasma.
    Thompson AR; Counts RB
    J Lab Clin Med; 1976 Dec; 88(6):922-9. PubMed ID: 993645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidurals in patients receiving thromboprophylaxis with unfractionated heparin three times a day: the value of activated partial thromboplastin time testing.
    Pace M; Koury K; Gulur P
    Anesth Analg; 2014 Nov; 119(5):1215-8. PubMed ID: 25225890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
    Adatya S; Sunny R; Fitzpatrick MJ; Colvin M; Thennapan T; John R; Dodge Zantek N; Pritzker M; Eckman P; Uriel N
    J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability in heparin sensitivity of APTT reagents.
    Bjornsson TD; Nash PV
    Am J Clin Pathol; 1986 Aug; 86(2):199-204. PubMed ID: 3739971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the value of the activated partial thrombo-plastin time (aptt) in monitoring heparin therapy.
    Teien AN; Abildgaard U
    Thromb Haemost; 1976 Jun; 35(3):592-7. PubMed ID: 989966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of heparin therapy with the activated partial thromboplastin time and chromogenic substrate assays.
    Fey MF; Lang M; Furlan M; Beck EA
    Thromb Haemost; 1987 Oct; 58(3):853-5. PubMed ID: 3481140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulant effect of unfractionated heparin in antithrombin-depleted plasma in vitro.
    Krulder JW; Strebus AF; Meinders AE; Briët E
    Haemostasis; 1996; 26(2):85-9. PubMed ID: 9119287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation among commercial activated partial thromboplastin time reagents in response to heparin.
    Shapiro GA; Huntzinger SW; Wilson JE
    Am J Clin Pathol; 1977 May; 67(5):477-80. PubMed ID: 857645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.